

ABSTRACT

The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a hydroximic acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

J10/084095 U.S. PTO

02/28/02

(51) International Patent Classification ⁶ : A61K 45/06		A1	(11) International Publication Number: WO 98/58676 (43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/IB98/00961 (22) International Filing Date: 22 June 1998 (22.06.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: P 97 01081 23 June 1997 (23.06.97) HU		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): N-GENE RESEARCH LABORATORIES INC. [US/US]; 10th floor, 575 Madison Avenue, New York, NY 10022 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only): SÜMEGI, Balázs [HU/HU]; Homokkő utca 7, H-7634 Pécs (HU).	
(74) Agent: KARÁCSONYI, Béla; Advopatent Office of Patent and Trademark Attorneys, P.O. Box 11, H-1251 Budapest (HU).		(54) Title: PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXIMIC ACID DERIVATIVE	
$ \begin{array}{c} \text{X} \quad \text{R} \\ \quad \\ \text{R}^3 - \text{A} - \text{C} - \text{N} - \text{O} - \text{CH}_2 - \text{CH} - \text{CH}_2 - \text{N} \\ \\ \text{B} \end{array} \quad \begin{array}{c} \text{Y} \\ \\ \text{R}^1 \\ \text{R}^2 \end{array} \quad \text{(I)} $			
(57) Abstract			
<p>The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a hydroximic acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.</p>			